News

Register today for OSCO’s Conference on 9-21-19

Posted on 9.12.2019

Join OSCO for our Fall Conference which will highlight the foremost research and strategies in Oncology that were presented at the 2019 Annual Meeting of the American Society of Clinical Oncology, Inc. (ASCO®) and other national oncology meetings.

This seminar … Read More

Merck announces new pack for KEYTRUDA®

Posted on 9.12.2019

Merck is pleased to announce the availability of a new pack for KEYTRUDA® (pembrolizumab)Injection 100 mg/4 mL (25 mg/mL) (“KEYTRUDA”).The new pack contains two 100mg/4 mL single-dose vials in a single carton. The price per vial of KEYTRUDA is not … Read More

Genentech announces FDA Approval of ROZLYTREK

Posted on 9.10.2019

Genentech is excited to share the news of a new FDA approval. ROZLYTREK™ (entrectinib) is now FDA approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.

ROZLYTREK is also FDA … Read More

FDA grants approval for POLIVY™

Posted on 9.10.2019

On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval for POLIVY™ (polatuzumab vedotin-piiq) in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise … Read More

Merck announces new FDA approval for KEYTRUDA

Posted on 8.22.2019

Merck is pleased to announce that KEYTRUDA has been approved by the FDA for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 [combined positive score (CPS) ≥10] as … Read More

US Food and Drug Administration approves INREBIC® for Treatment

Posted on 8.21.2019

INREBIC® (fedratinib) capsules, a product from Celgene, is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).

INDICATION

INREBIC® (fedratinib) is indicated for the treatment of adult … Read More

KEYTRUDA approved by FDA for first-line treatment of patients with HNSCC

Posted on 6.19.2019

Merck is pleased to announce that KEYTRUDA, in combination with platinum and fluorouracil (FU), has been approved by the FDA for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

KEYTRUDA … Read More

Pfizer announces a first-line combination Rx for advanced RCC.

Posted on 5.21.2019

 

NOW APPROVED
new, first-line immunotherapy (IO) and tyrosine kinase inhibitor (TKI) combination for patients with advanced renal cell carcinoma (RCC)
Learn more ›
Read More

CMS finalizes rule which forces drug manufacturers to provide the list price for their products in direct-to-consumer ads.

Posted on 5.15.2019

The new policy is aimed at increasing transparency and vehemently opposed by industry. The new policy will apply to drugs or biologics with list prices greater than $35 for a month’s supply or the normal course of therapy, which HHS … Read More

Merck announces new FDA approval for KEYTRUDA

Posted on 5.3.2019

Merck announces new FDA approval for KEYTRUDA

Merck is pleased to announce that KEYTRUDA, in combination with axitinib, has been approved by the FDA for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

  • PD-L1 diagnostic testing is
Read More